IDSA will update our site moving forward with the term "mpox" to reduce stigma and other issues associated with prior terminology. This change is aligned with the Nov. 28, 2022, World Health Organization decision. Some webpages and materials created prior to this date may still reflect the old name.
Mpox is a rare disease caused by infection with a virus. Despite being originally named “monkeypox,” the source of the disease remains unknown.
Human-to-human transmission occurs primarily through direct contact with infected lesions or fluids or contact with contaminated materials like clothing or bedding. It also can be spread by respiratory droplets during prolonged face-to-face contact. Mpox has an average incubation period of 6 to 13 days, with a range of 5 to 21 days.
Although a majority of cases in the current phase of the 2022 mpox outbreak have occurred among gay and bisexual men, anyone can be affected regardless of sexual orientation. While evidence to date in the current outbreak has not identified a new mechanism of infection unique to sexual transmission, mpox can be transmitted through prolonged physical contact, including intimate sexual contact. The latest case data by state and by age, gender, race/ethnicity and symptoms are available from the Centers for Disease Control and Prevention.
For the Public
- IDSA Mpox Fact Sheet
- IDSA Mpox Fact Sheet - Spanish
- Monkeypox in the U.S.: An Update for Clinicians and the LGBTQ Community - June 13, 2022
- Congressional Briefing: Challenges on the Front Lines of Monkeypox
- Sep 20, 2022
- MPV Resource Needs Brief - September 22, 2022
- MPV Equitable Testing Access Bill News Release - August 10, 2022
- IDSA Statement on MPV Public Health Emergency Declaration - August 4, 2022
- IDSA and HIVMA Applaud New Administration Monkeypox Coordinators, Call for Funding and Improved Vaccine Supply and Access – August 2, 2022
- IDSA and HIVMA Letter to White House Office of Science and Technology Policy on Research Priorities – August 1, 2022
- IDSA Statement on Increase in Monkeypox Vaccine Supply – July 28, 2022
- Monkeypox Virus in the US: Perspectives from the Front Lines: Congressional briefing July 25, 2022
- HHS Monkeypox Letter – July 22, 2022 sent by IDSA with 40 stakeholder groups signing
- IDSA/HIVMA Support Rapid CDC Response to Monkeypox Treatment Access Issues – July 21, 2022
- MPV Federal Funding Letter to Congress – July 19, 2022
- IDSA and HIVMA Welcome Administration’s Commitment to Bolstering Monkeypox Testing and Vaccination – June 30, 2022
- IDSA/HIVMA Statement: Stigma Has No Place in Public Health – May 26, 2022
- Mpox in the U.S.: Resources for HIV Clinicians
- IDSA/CDC Clinician Call - Monkeypox: Updates on Testing, Vaccination & Treatment Slide Deck
- Identify, Isolate and Inform: What You Need to Know About Recent Cases of Monkeypox in the United States
- Monkeypox in the U.S.: An Update for Clinicians and the LGBTQ Community
- A5418 Clinical Trial Study of Tecovirimat for Human Monkeypox Virus (STOMP)
- CDC Clinical Considerations for Pain Management
- CDC Guidance for Tecovirimat Use Under Expanded Access Investigational New Drug Protocol
- CDC Obtaining and Using TPOXX (Tecovirimat) for Treatment of Mpox
- CDC Dear Colleague Letter on Pain Control
- Epic SmartText Available for Ticovirimat (TPOXX) Form A (Patient Intake Form) and Form B (Clinical Outcome Form): Mass General Brigham has posted to the Epic UserWeb for use by others an Epic SmartText to facilitate completion of Form A (Patient Intake Form) of the Expanded Access - New Investigational Drug protocol required for tecovirimat (TPOXX).
- CDC Health Alert Network Update, July 30, 2022 (HIV, Children & Adolescents, Pregnant People)
- CDC Clinical Considerations for Treatment and Prophylaxis of Mpox Infection in People With HIV
- CDC Clinical Considerations for Mpox in Children and Adolescents
- CDC Clinical Considerations for Mpox in People Who Are Pregnant or Breastfeeding
Infection Prevention & Control